Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

NCT04107142 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Triple Negative Breast Cancer
Sarcoma
Nasopharyngeal Carcinoma
Prostate Cancer
Gastric Cancer

Interventions

BIOLOGICAL: Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell

Sponsor

CytoMed Therapeutics Pte Ltd